Shandong Weigao Orthopaedic Device Reports 8% YoY Drop in Q3 Net Profit to RMB65.45 Million

Deep News10-30

On October 30, Shandong Weigao Orthopaedic Device Co.,Ltd. (688161) released its Q3 2025 financial report. The company reported revenue of RMB1.11 billion, marking a 2.1% year-on-year increase. Net profit attributable to shareholders reached RMB207 million, up 26.2% YoY, while adjusted net profit stood at RMB194 million, rising 22.1% YoY. Operating cash flow surged 31.9% to RMB250 million, with diluted EPS at RMB0.5185.

For the third quarter alone, revenue grew 9.8% YoY to RMB365 million. However, net profit attributable to shareholders declined 8.0% YoY to RMB65.45 million, and adjusted net profit fell 16.2% to RMB58.65 million. Q3 EPS was RMB0.1636.

As of Q3-end, total assets amounted to RMB5.093 billion, up 2.9% from year-end 2024. Shareholders' equity increased 3.0% to RMB4.073 billion.

The report outlined the company's core business focus on R&D, production, and sales of orthopedic medical devices, including joint reconstruction, minimally invasive spine solutions, and tissue repair products. The joint product line drove revenue growth through sales model adjustments and product mix optimization. The spine minimally invasive line responded to clinical demand shifts with updated offerings, boosting sales. The tissue repair line expanded product indications, strengthening its academic positioning in specialized markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174436245?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174436245","market":"us","top_or_hot":-1,"title":"Shandong Weigao Orthopaedic Device Reports 8% YoY Drop in Q3 Net Profit to RMB65.45 Million","media":"Deep News","content":"<p>On October 30, Shandong Weigao Orthopaedic Device Co.,Ltd. (688161) released its Q3 2025 financial report. The company reported revenue of RMB1.11 billion, marking a 2.1% year-on-year increase. Net profit attributable to shareholders reached RMB207 million, up 26.2% YoY, while adjusted net profit stood at RMB194 million, rising 22.1% YoY. Operating cash flow surged 31.9% to RMB250 million, with diluted EPS at RMB0.5185.</p>\n<p>For the third quarter alone, revenue grew 9.8% YoY to RMB365 million. However, net profit attributable to shareholders declined 8.0% YoY to RMB65.45 million, and adjusted net profit fell 16.2% to RMB58.65 million. Q3 EPS was RMB0.1636.</p>\n<p>As of Q3-end, total assets amounted to RMB5.093 billion, up 2.9% from year-end 2024. Shareholders' equity increased 3.0% to RMB4.073 billion.</p>\n<p>The report outlined the company's core business focus on R&D, production, and sales of orthopedic medical devices, including joint reconstruction, minimally invasive spine solutions, and tissue repair products. The joint product line drove revenue growth through sales model adjustments and product mix optimization. The spine minimally invasive line responded to clinical demand shifts with updated offerings, boosting sales. The tissue repair line expanded product indications, strengthening its academic positioning in specialized markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Weigao Orthopaedic Device Reports 8% YoY Drop in Q3 Net Profit to RMB65.45 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Weigao Orthopaedic Device Reports 8% YoY Drop in Q3 Net Profit to RMB65.45 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-30 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On October 30, Shandong Weigao Orthopaedic Device Co.,Ltd. (688161) released its Q3 2025 financial report. The company reported revenue of RMB1.11 billion, marking a 2.1% year-on-year increase. Net profit attributable to shareholders reached RMB207 million, up 26.2% YoY, while adjusted net profit stood at RMB194 million, rising 22.1% YoY. Operating cash flow surged 31.9% to RMB250 million, with diluted EPS at RMB0.5185.</p>\n<p>For the third quarter alone, revenue grew 9.8% YoY to RMB365 million. However, net profit attributable to shareholders declined 8.0% YoY to RMB65.45 million, and adjusted net profit fell 16.2% to RMB58.65 million. Q3 EPS was RMB0.1636.</p>\n<p>As of Q3-end, total assets amounted to RMB5.093 billion, up 2.9% from year-end 2024. Shareholders' equity increased 3.0% to RMB4.073 billion.</p>\n<p>The report outlined the company's core business focus on R&D, production, and sales of orthopedic medical devices, including joint reconstruction, minimally invasive spine solutions, and tissue repair products. The joint product line drove revenue growth through sales model adjustments and product mix optimization. The spine minimally invasive line responded to clinical demand shifts with updated offerings, boosting sales. The tissue repair line expanded product indications, strengthening its academic positioning in specialized markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0251","symbol_name":"专用设备","start_time":0,"source_url":"","article_id":"1174436245","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174436245","pubTimestamp":1761818445,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On October 30, Shandong Weigao Orthopaedic Device Co.,Ltd. (688161) released its Q3 2025 financial report. The company reported revenue of RMB1.11 billion, marking a 2.1% year-on-year increase. Net...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688161":"威高骨科","BK0251":"专用设备"},"translate_title":"山东威高骨科第三季度净利润同比下降8%至人民币6,545万元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688161":1},"content_text":"On October 30, Shandong Weigao Orthopaedic Device Co.,Ltd. (688161) released its Q3 2025 financial report. The company reported revenue of RMB1.11 billion, marking a 2.1% year-on-year increase. Net profit attributable to shareholders reached RMB207 million, up 26.2% YoY, while adjusted net profit stood at RMB194 million, rising 22.1% YoY. Operating cash flow surged 31.9% to RMB250 million, with diluted EPS at RMB0.5185.\nFor the third quarter alone, revenue grew 9.8% YoY to RMB365 million. However, net profit attributable to shareholders declined 8.0% YoY to RMB65.45 million, and adjusted net profit fell 16.2% to RMB58.65 million. Q3 EPS was RMB0.1636.\nAs of Q3-end, total assets amounted to RMB5.093 billion, up 2.9% from year-end 2024. Shareholders' equity increased 3.0% to RMB4.073 billion.\nThe report outlined the company's core business focus on R&D, production, and sales of orthopedic medical devices, including joint reconstruction, minimally invasive spine solutions, and tissue repair products. The joint product line drove revenue growth through sales model adjustments and product mix optimization. The spine minimally invasive line responded to clinical demand shifts with updated offerings, boosting sales. The tissue repair line expanded product indications, strengthening its academic positioning in specialized markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174436245","isCrawlerRequest":true}